Morgan Stanley raised price targets and ratings for Ultragenyx Pharmaceutical.
9 reports, 1 independent
Updated Sep 23
Mostly repetition
- Reports
- 9
- Developments
- 1
- Repetition
- 89%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Morgan Stanley raised price targets and ratings for Ultragenyx Pharmaceutical.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Ultragenyx Pharmaceutical
biopharmaceutical company based in Novato, California, United States
Nothing else this week.
-
Morgan Stanley
U.S. investment bank
Related events
- Morgan Stanley gave Micron Technology an overweight rating and included it in a list of major stocks.
- Morgan Stanley analysts hiked price targets for Salesforce.
- Morgan Stanley issued a rating and price target for Trevi Therapeutics, Inc. on August 28, 2026.
- Morgan Stanley and Royal Bank of Canada adjusted ratings and price targets for TransDigm Group Incorporated stock.
- Morgan Stanley raised the price objective for Estee Lauder Companies Inc. on September 10th.